首页|期刊导航|中华医学杂志(英文版)|Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-na(i)ve chronic hepatitis B patients: a prospective and randomized controlled trial
Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-na(i)ve chronic hepatitis B patients: a prospective and randomized controlled trial
Jing-Mao Yang Xiao Ming Xian Li Shao-Ping Huang Ji-Lin Cheng Li-Ping Chen Ya-Jie Wang Bei Lyu Hong Zhao Zhi-Yin Shang Jun Li Zhen-Yu Fan Sheng-Di Wu
中华医学杂志(英文版)2020,Vol.133Issue(14):1639-1648,10.
中华医学杂志(英文版)2020,Vol.133Issue(14):1639-1648,10.DOI:10.1097/CM9.0000000000000857
Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-na(i)ve chronic hepatitis B patients: a prospective and randomized controlled trial
Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-na(i)ve chronic hepatitis B patients: a prospective and randomized controlled trial
摘要
关键词
Peg-interferon/Entecavir/Chronic hepatitis B/Curative effect/Combination therapyKey words
Peg-interferon/Entecavir/Chronic hepatitis B/Curative effect/Combination therapy引用本文复制引用
Jing-Mao Yang,Xiao Ming,Xian Li,Shao-Ping Huang,Ji-Lin Cheng,Li-Ping Chen,Ya-Jie Wang,Bei Lyu,Hong Zhao,Zhi-Yin Shang,Jun Li,Zhen-Yu Fan,Sheng-Di Wu..Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-na(i)ve chronic hepatitis B patients: a prospective and randomized controlled trial[J].中华医学杂志(英文版),2020,133(14):1639-1648,10.基金项目
This study was supported by grants from the Major Science and Technology Special Project of China Thirteenth Five-year Plan (No.2013ZX10002004,No.2017ZX10203202-003-007) (No.2013ZX10002004,No.2017ZX10203202-003-007)
and partly supported by the Shanghai Science and Technology Development Fund (No.17411969500),and the Shanghai Public Health Clinical Center Fund (No.XKJS-2019HBV-06,No.KY-GW-2019-32). (No.17411969500)